The DOI matches its Crossref record; 257 of the 257 references it cites were found in a registry or an index.
Glioblastoma multiforme: State of the art and future therapeutics
Open accessAbstract
BACKGROUND: Glioblastoma multiforme (GBM) is the most common and lethal primary malignancy of the central nervous system (CNS). Despite the proven benefit of surgical resection and aggressive treatment with chemo- and radiotherapy, the prognosis remains very poor. Recent advances of our understanding of the biology and pathophysiology of GBM have allowed the development of a wide array of novel therapeutic approaches, which have been developed. These novel approaches include molecularly targeted therapies, immunotherapies, and gene therapy. METHODS: We offer a brief review of the current standard of care, and a survey of novel therapeutic approaches for treatment of GBM. RESULTS: Despite promising results in preclinical trials, many of these therapies have demonstrated limited therapeutic efficacy in human clinical trials. Thus, although survival of patients with GBM continues to slowly improve, treatment of GBM remains extremely challenging. CONCLUSION: Continued research and development of targeted therapies, based on a detailed understanding of molecular pathogenesis can reasonably be expected to yield improved outcomes for patients with GBM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–257 of 257
Scaringi, C., Minniti, G. C., Caporello, P., & Enrici, R. M. (2012) · PubMed · Cited by 89
Sloan, A. E., Dansey, R., Zamorano, L. J., Barger, G. R., Hamm, C. M., Díaz, F. G., Baynes, R., & Wood, G. (2000) · Neurosurgical FOCUS · doi:10.3171/foc.2000.9.6.10 · Cited by 87
Gene Therapy and Targeted Toxins for Glioma
Castro, M. G., Candolfi, M., Kroeger, K. M., King, G. D., Curtin, J. F., Yagiz, K., Mineharu, Y., Assi, H. H., Wibowo, M., Muhammad, A. K. M. G., et al. (2011) · Current Gene Therapy · doi:10.2174/156652311795684722 · Cited by 86
Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety
Kang, T. Y., Jin, T., Elinzano, H., & Peereboom, D. M. (2008) · Journal of Neuro-Oncology · doi:10.1007/s11060-008-9599-0 · Cited by 85
Debinski, W., Miner, R., Leland, P., Obiri, N. I., & Puri, R. K. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.37.22428 · Cited by 83
Vredenburgh, J. J., Desjardins, A., Kirkpatrick, J. P., Reardon, D. A., Peters, K. B., Herndon, J. E., Marcello, J. E., Bailey, L., Threatt, S., Sampson, J. H., et al. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.08.058 · Cited by 82
Molecular targeted therapy in recurrent glioblastoma: current challenges and future directions
Patel, M. D., Vogelbaum, M. A., Barnett, G. H., Jalali, R., & Ahluwalia, M. S. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.703177 · Cited by 80
Integrin αvβ3-Targeted Radioimmunotherapy of Glioblastoma Multiforme
Veeravagu, A., Liu, Z., Niu, G., Chen, K., Jia, B., Cai, W., Jin, C., Hsu, A. R., Connolly, A. J., Tse, V., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0797 · Cited by 80
Cell- and peptide-based immunotherapeutic approaches for glioma
Yamanaka, R. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.03.003 · Cited by 76
Jacobs, A., Breakefield, X. O., & Fraefel, C. (1999) · Neoplasia · doi:10.1038/sj.neo.7900056 · Cited by 75
Effect of imaging and catheter characteristics on clinical outcome for patients in the PRECISE study
Mueller, S., Polley, M. C., Lee, B. J., Kunwar, S., Pedain, C., Wembacher-Schroeder, E., Mittermeyer, S., Westphal, M., Sampson, J. H., Vogelbaum, M. A., et al. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0255-0 · Cited by 74
Boiardi, A., Silvani, A., Ruffini, P. A., Rivoltini, L., Parmiani, G., Broggi, G., & Salmaggi, A. (1994) · Cancer Immunology Immunotherapy · doi:10.1007/bf01533386 · Cited by 74
Pitter, K. L., Galbán, C. J., Galbán, S., Tehrani, O. S., Li, F., Charles, N. A., Bradbury, M. S., Becher, O. J., Chenevert, T. L., Rehemtulla, A., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0014545 · Cited by 73
Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma
Reardon, D. A., Vredenburgh, J. J., Sykes, A. D., Desjardins, A., Peters, K. B., Gururangan, S., Sathornsumetee, S., Rich, J. N., Herndon, J. E., & Friedman, H. S. (2011) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0631-4 · Cited by 72
Recent developments on immunotherapy for brain cancer
Wainwright, D. A., Nigam, P., Thaçi, B., Dey, M., & Lesniak, M. S. (2012) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2012.679929 · Cited by 71
Gilbert, M. R., Dignam, J., Won, M., Blumenthal, D. T., Vogelbaum, M. A., Aldape, K. D., Colman, H., Chakravarti, A., Jeraj, R., Armstrong, T. S., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.18_suppl.1 · Cited by 70
Holladay, F. P., Heitz, T., Bayer, W. L., & Wood, G. W. (1996) · Journal of Neuro-Oncology · doi:10.1007/bf00177482 · Cited by 66
Todhunter, D. A., Hall, W. A., Rustamzadeh, E., Shu, Y., Doumbia, S., & Vallera, D. A. (2004) · Protein Engineering Design and Selection · doi:10.1093/protein/gzh023 · Cited by 65
Rainov, N. G., Kramm, C. M., Banning, U., Riemann, D., Holzhausen, H., Heidecke, V., Burger, K. J., Burkert, W. L., & Körholz, D. (2000) · Gene Therapy · doi:10.1038/sj.gt.3301311 · Cited by 65
Fukai, J., Nishio, K., Itakura, T., & Koizumi, F. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00945.x · Cited by 64
Dembinski, J. L., Spaeth, E. L., Fueyo-Margareto, J., Gomez‐Manzano, C., Studeny, M., Andreeff, M., & Marini, F. C. (2009) · Cancer Gene Therapy · doi:10.1038/cgt.2009.67 · Cited by 63
Novel Therapies in Glioblastoma
Perry, J., Okamoto, M., Guiou, M., Shirai, K., Errett, A., & Chakravarti, A. (2012) · Neurology Research International · doi:10.1155/2012/428565 · Cited by 62
Chemotherapeutic wafers for High Grade Glioma
Hart, M. G., Grant, R., Garside, R., Rogers, G., Somerville, M., & Stein, K. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007294 · Cited by 61
Long, Z., Lie-ping, L., Grooms, T., Lockey, C., Nader, K., Mychkovsky, I., Mueller, S. N., Burimski, I., Ryan, P. C., Kikuchi, G. E., et al. (1998) · Human Gene Therapy · doi:10.1089/hum.1998.9.8-1165 · Cited by 57
Raizer, J. J., Abrey, L. E., Lassman, A. B., Chang, S., Lamborn, K. R., Kuhn, J. G., Yung, W. K. A., Gilbert, M. R., Aldape, K., Wen, P. Y., et al. (2009) · Neuro-Oncology · doi:10.1093/neuonc/nop017 · Cited by 56
Gene delivery and gene therapy with herpes simplex virus-based vectors
Latchman, D. S. (2001) · Gene · doi:10.1016/s0378-1119(01)00322-5 · Cited by 55
Development of a second‐generation oncolytic Herpes simplex virus expressing TNFα for cancer therapy
Han, Z., Assenberg, M., Liu, B., Wang, Y. B., Simpson, G. R., Thomas, S., & Coffin, R. S. (2007) · The Journal of Gene Medicine · doi:10.1002/jgm.999 · Cited by 54
Angiogenesis in malignant primary and metastatic brain tumors
Reijneveld, J. C., Voest, E. E., & TAPHOORN, M. J. B. (2000) · Journal of Neurology · doi:10.1007/s004150070128 · Cited by 53
Design and application of oncolytic HSV vectors for glioblastoma therapy
Grandi, P., Peruzzi, P., Reinhart, B., Cohen, J. B., Chiocca, E. A., & Glorioso, J. C. (2009) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.9 · Cited by 52
Ehtesham, M., Black, K. L., & Yu, J. S. (2004) · Cancer Control · doi:10.1177/107327480401100307 · Cited by 51
Gene therapy and virotherapy: novel therapeutic approaches for brain tumors.
Kroeger, K. M., Muhammad, A. K. M. G., Baker, G. J., Assi, H. H., Wibowo, M., Xiong, W., Yagiz, K., Candolfi, M., Lowenstein, P. R., & Castro, M. G. (2010) · PubMed · Cited by 50
Targeted Toxins in Brain Tumor Therapy
Li, Y. M., & Hall, W. A. (2010) · Toxins · doi:10.3390/toxins2112645 · Cited by 50
Stupp, R., Hegi, M. E., Gorlia, T., Erridge, S., Grujičić, D., Steinbach, J. P., Wick, W., Tarnawski, R., Nam, D., Weyerbrock, A., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.18_suppl.lba2009 · Cited by 48
Jacobs, A., Breakefield, X. O., & Fraefel, C. (1999) · Neoplasia · doi:10.1038/sj.neo.7900055 · Cited by 45
Intracranial therapy of glioblastoma with the fusion protein DTAT in immunodeficient mice
Rustamzadeh, E., Hall, W. A., Todhunter, D. A., Vallera, V. D., Low, W. C., Liu, H., Panoskaltsis‐Mortari, A., & Vallera, D. A. (2006) · International Journal of Cancer · doi:10.1002/ijc.22278 · Cited by 44
Proteolysis and invasiveness of brain tumors: Role of urokinase-type plasminogen activator receptor
Mohanam, S., Sawaya, R. A., Yamamoto, M., Bruner, J. M., Nicholson, G. L., & Rao, J. S. (1994) · Journal of Neuro-Oncology · doi:10.1007/bf01052890 · Cited by 41
Toward Effective Immunotherapy for the Treatment of Malignant Brain Tumors
Mitchell, D. A., & Sampson, J. H. (2009) · Neurotherapeutics · doi:10.1016/j.nurt.2009.04.003 · Cited by 41
Gene and Viral Therapy for Glioblastoma: A Review of Clinical Trials and Future Directions
Mohyeldin, A., & Chiocca, E. A. (2012) · The Cancer Journal · doi:10.1097/ppo.0b013e3182458b13 · Cited by 41
Rahmathulla, G., Hovey, Hashemi-Sardraei, & Ahluwalia, M. S. (2013) · OncoTargets and Therapy · doi:10.2147/ott.s38628 · Cited by 40
Long, Z., Lu, P. Y., Grooms, T., Mychkovsky, I., Westley, T., Fitzgerald, T. A., Sharma-Chibber, S., Shand, N., McGarrity, G. J., & Otto, E. (1999) · Human Gene Therapy · doi:10.1089/10430349950018490 · Cited by 39
Gene Therapy in Brain Tumours: Implications of the Size of Glioblastoma on its Curability
Izquierdo, M., Cortés, M. L., Martı́n, V., de Felipe, P., Izquierdo, J. M., Përez‐Higueras, A., Jf, P., Isla, A., & Blazquez, M. (1997) · Acta neurochirurgica. Supplementum · doi:10.1007/978-3-7091-6513-3_21 · Cited by 36
Molecular Targeting with Recombinant Cytotoxins of Interleukin-13 Receptor α 2-expressing Glioma
Mintz, A., Gibo, D. M., Madhankumar, A. B., & Debinski, W. (2003) · Journal of Neuro-Oncology · doi:10.1007/bf02700026 · Cited by 36
Rustamzadeh, E., Li, C., Doumbia, S., Hall, W. A., & Vallera, D. A. (2003) · Journal of Neuro-Oncology · doi:10.1023/a:1026238331739 · Cited by 35
Clinical Applications of a Peptide-Based Vaccine for Glioblastoma
Kanaly, C. W., Ding, D., Heimberger, A. B., & Sampson, J. H. (2009) · Neurosurgery Clinics of North America · doi:10.1016/j.nec.2009.09.001 · Cited by 31
Gene Therapy for High-Grade Glioma
Iwami, K., Natsume, A., & Wakabayashi, T. (2010) · Neurologia medico-chirurgica · doi:10.2176/nmc.50.727 · Cited by 31
Rustamzadeh, E., Vallera, D. A., Todhunter, D. A., Low, W. C., Panoskaltsis‐Mortari, A., & Hall, W. A. (2005) · Journal of Neuro-Oncology · doi:10.1007/s11060-005-9051-7 · Cited by 30
Cetuximab Insufficiently Inhibits Glioma Cell Growth Due to Persistent EGFR Downstream Signaling
Hasselbalch, B., Lassen, U., Poulsen, H. S., & Stockhausen, M. (2010) · Cancer Investigation · doi:10.3109/07357907.2010.483506 · Cited by 30
Cellular Immunotherapy for High-Grade Glioma
Chow, K. K. H., & Gottschalk, S. M. (2011) · Immunotherapy · doi:10.2217/imt.10.110 · Cited by 28
Cornforth, A. N., Fowler, A. W., Carbonell, D. J., Fan, E., & Dillman, R. O. (2011) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2011.0959 · Cited by 27
Cellular-Based Immunotherapies for Patients with Glioblastoma Multiforme
Xu, X., Stockhammer, F., & Schmitt, M. W. (2012) · Clinical and Developmental Immunology · doi:10.1155/2012/764213 · Cited by 25
Early Genetic Changes Involved in Low-Grade Astrocytic Tumor Development
Arjona, D., REY, J. A., & Taylor, S. (2006) · Current Molecular Medicine · doi:10.2174/156652406778195017 · Cited by 18
Clinical Trials in Brain Tumor Surgery
Hoover, J. M., Chang, S. M., & Parney, I. F. (2010) · Neuroimaging Clinics of North America · doi:10.1016/j.nic.2010.04.006 · Cited by 17
Stem Cells as Delivery Vehicles for Oncolytic Adenoviral Virotherapy
Kranzler, J., Tyler, M. A., Sonabend, A. M., Ulasov, I. V., & Lesniak, M. S. (2009) · Current Gene Therapy · doi:10.2174/156652309789753347 · Cited by 17
Crossing the boundaries: stem cells and gene therapy.
Ferguson, S. D., Ahmed, A. U., Thaçi, B., Mercer, R. W., & Lesniak, M. S. (2010) · PubMed · Cited by 16
Gene Therapy with Viral Vectors
Jolly, D. J. (2003) · BioProcessing Journal · doi:10.12665/j25.jolly · Cited by 16
Clinical Trials of Small Molecule Inhibitors in High-Grade Glioma
Day, S. E., & Waziri, A. E. (2012) · Neurosurgery Clinics of North America · doi:10.1016/j.nec.2012.04.004 · Cited by 14
(2003) · PubMed
Cited by
Glioblastoma: Overview of Disease and Treatment
Davis, M. (2016) · Clinical Journal of Oncology Nursing · doi:10.1188/16.cjon.s1.2-8 · Cited by 1,205
Glioblastoma multiforme: Pathogenesis and treatment
Alifieris, C., & Trafalis, D. T. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.05.005 · Cited by 820
Survival in glioblastoma: a review on the impact of treatment modalities
Delgado-López, P. D., & Corrales-García, E. M. (2016) · Clinical and Translational Oncology · doi:10.1007/s12094-016-1497-x · Cited by 659
Epidemiology and Outcome of Glioblastoma
Department of Neurosurgery, J. U. H. A. M. S., TAMIMI, A. F., JUWEID, M., & Department of Radiology and Nuclear Medicine, J. U. H. A. M. S. (2017) · Glioblastoma · doi:10.15586/codon.glioblastoma.2017.ch8 · Cited by 484
Temozolomide and Other Alkylating Agents in Glioblastoma Therapy
Strobel, H., Baisch, T., Fitzel, R., Schilberg, K., Siegelin, M. D., Karpel-Massler, G., Debatin, K.-M., & Westhoff, M.-A. (2019) · Biomedicines · doi:10.3390/biomedicines7030069 · Cited by 279
Metadata
- Authors
- Harter, D., Wilson, T., & Karajannis, M.
- Venue
- Surgical Neurology International
- Publisher
- Scientific Scholar
- Published
- 2014
- Volume
- 5
- Issue
- 1
- Pages
- 64
- ISSN
- 2152-7806 (ISSN-L)
- OpenAlex
- W2003438982
- Cited by
- 327
- References
- 257
- FWCI
- 12.60
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.